A Study to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor
- Conditions
- Kidney Transplantation Cytomegalovirus (CMV) Negative Recipients
- Interventions
- Drug: Placebo
- Registration Number
- NCT01974206
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Brief Summary
The purpose of this study was to evaluate the efficacy of ASP0113 compared to placebo in reducing the incidence of cytomegalovirus (CMV) viremia in CMV-seronegative subjects receiving a kidney from a CMV-seropositive donor. This study also evaluated the safety of ASP0113 in this patient population.
- Detailed Description
Participants were followed for one year after first study drug injection. This was the primary study period.
Participants were followed for 4.5 years after completion of the primary study to assess long-term safety of the vaccine.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 150
- CMV negative subject having received a CMV seropositive kidney (living or deceased)
- Participant started valganciclovir or ganciclovir within 10 days of transplant and had received it through Randomization.
- Participant underwent a course of CMV-specific prophylactic therapy with antiviral drugs with a duration of greater than 100 days.
- Participant had received from one month prior to transplant or planned to receive CMV immunoglobulin.
- Participant had CMV viremia or CMV disease from time of transplant until time of Randomization.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description ASP0113 ASP0113 Participants received 1 mL of 5 mg/mL of ASP0113 via injection in the deltoid muscle alternating sides with each dose on days 30, 60, 90, 120 and 180 in relation to the day of transplant (Day 0). Placebo Placebo Participants received 1 mL of 5 mg/mL of placebo via injection in the deltoid muscle alternating sides with each dose on days 30, 60, 90, 120 and 180 in relation to the day of transplant (Day 0).
- Primary Outcome Measures
Name Time Method Percentage of Participants With CMV Viremia Through 1 Year Post First Study Drug Injection From first study dose injection (day 1) up to one year post study drug injection (up to Day 380) CMV viremia was defined as presence of cytomegalovirus as measured in plasma viral load of ≥ 1000 IU/mL by central laboratory assay. A participant who discontinued the study without a positive CMV viral load was imputed as having a CMV viremia. A participant who had more than one viral load ≥ 1000 IU/mL by central assay was counted once in this summary. CMV viral loads after first injection (Day 1) through Day 380 (scheduled or unscheduled) were included in the analysis.
- Secondary Outcome Measures
Name Time Method Percentage of Participants With Plasma Viral Load ≥ The Lower Limit of Quantification (LLOQ) Assessed by Central Laboratory (Primary Study Period) From first study dose injection (day 1) up to one year post study drug injection (up to Day 380) The central laboratory had the LLOQ level for CMV viral load assessment. When the viral load was below the LLOQ the actual reading was not possible and was denoted as ≤LLOQ. If the participant had any CMV viral load assessments greater than the LLOQ, set up by the central laboratory, participant was classified as viremic and was included in the analysis.
Percentage of Participants Who Took Adjudicated CMV-specific Antiviral Therapy for the Treatment of CMV Viremia or Disease (Primary Study Period) From first study dose injection (day 1) up to one year post study drug injection (up to Day 380) An independent panel of medical experts reviewed/adjudicated events of CMV-specific AVT for treatment of CMV viremia or disease.
Percentage of Participants With Graft Survival (Long-term Follow up) Month 18, 30, 42, 54, and 66 Graft survival was defined for any participant that did not fit the definition of graft loss. Graft loss was defined as participant death, re-transplant, nephrectomy, or return to permanent dialysis (i.e., for \> 30 days). Missing values for graft survival were not included in the denominator when making the proportion.
Percentage of Participants With Adjudicated CMV-Associated Disease, Including CMV Syndrome and CMV Tissue-Invasive Disease (Primary Study Period) From first study dose injection (day 1) up to one (up to Day 380) year post study drug injection An independent panel of medical experts reviewed/adjudicated events of CMV-associated disease including CMV syndrome and tissue invasive disease, which were defined according to the American Society of Transplantation Recommendations for Screening, Monitoring and Reporting of Infectious Complications in Immunosuppression Trials in Recipients of Organ Transplantation 2006.
Percentage of Participants With Graft Survival (Primary Study Period) From first study dose injection (day 1) up to one year post study drug injection (up to Day 380) Graft survival was defined for any participant that did not fit the definition of graft loss. Graft loss was defined as participant death, re-transplant, nephrectomy, or return to permanent dialysis (i.e., for \> 30 days). Missing values for graft survival were not included in the denominator when making the proportion. The analysis population was the FAS.
Trial Locations
- Locations (53)
Site US10026
🇺🇸Phoenix, Arizona, United States
Site US10003
🇺🇸Los Angeles, California, United States
Site US10004
🇺🇸San Diego, California, United States
Site US10036
🇺🇸San Francisco, California, United States
Site US10037
🇺🇸San Francisco, California, United States
Site US10044
🇺🇸Aurora, Colorado, United States
Site US10018
🇺🇸New Haven, Connecticut, United States
Site US10058
🇺🇸Atlanta, Georgia, United States
Site US10013
🇺🇸Atlanta, Georgia, United States
Site US10030
🇺🇸Chicago, Illinois, United States
Scroll for more (43 remaining)Site US10026🇺🇸Phoenix, Arizona, United States